Atelerix - the overall objective of this contract is to plan and execute a phase 1A clinical trial (hereafter referred to as the ?phase 1A trial?) of the novel small molecule atlx-0199 in 30 normal…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00053
- Awardee
-
Atelerix Life Sciences Inc. UEI TD8NL4UWNVW8
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $68,115
Award facts
- Opportunity
-
- EZBAA22100SOL00003 Solicitation number
- Contract value 100% obligated
- $68,115.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 100 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Charlottesville, VA, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$680,885 | |
| Original award | $749,000 |
About this award
This is a $68,115.00 Firm Fixed Price contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Atelerix Life Sciences Inc. for a Phase 1A clinical trial of the novel small molecule ATLX-0199. The objective of the trial is to evaluate the compound in 30 normal healthy subjects. This contract is not set aside and is part of the ATELERIX - PROOF-OF-CONCEPT CLINICAL TRIAL FOR A NOVEL RESPIRATORY STIMULANT major program. The work will be performed in Charlottesville, VA and has a completion date of July 23, 2024.
Description
Atelerix - the overall objective of this contract is to plan and execute a phase 1A clinical trial (hereafter referred to as the ?phase 1A trial?) of the novel small molecule atlx-0199 in 30 normal healthy subjects. The goal of the clinical trial is
Quick answers
Who was awarded contract 75A50123C00053?
75A50123C00053 was awarded to Atelerix Life Sciences Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on September 14, 2023.
How much is contract 75A50123C00053 worth?
The government has obligated $68,115 on 75A50123C00053.
Was contract 75A50123C00053 competed?
The extent of competition for 75A50123C00053 was competed under sap. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award